Ikena Oncology Inc

NASDAQ:IKNA   1:00:00 PM EDT
2.36
-0.20 (-7.81%)
2:37:51 PM EDT: $2.09 -0.27 (-11.44%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)78.88M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.96 Million
Adjusted EPS-$0.15
See more estimates
10-Day MA$2.30
50-Day MA$2.94
200-Day MA$4.76
See more pivots

Ikena Oncology Inc Stock, NASDAQ:IKNA

645 Summer Street, Suite 101, Boston, Massachusetts 02210
United States of America
Phone: +1.857.273.8343
Number of Employees: 67

Description

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.